Skip to content
You are now leaving https://www.ionispharma.com to visit

Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients with all forms of TTR amyloidosis BOSTON and CARLSBAD, Calif., Sept.